drugset / Trial / NCT00543075
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
Non-randomizedSingle-groupOpen-labelHealth-services research
Summary
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
Timeline
- Start
- 2006-05
- Primary completion
- 2007-11
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oblimersen sodium | Antisense oligonucleotide | 3 mg/kg | Intravenous |